Veraxa Biotech director reports 7,932-share holding

Veraxa Biotech Holding AG director reports initial shareholdings.

Rhea-AI Filing Summary

Veraxa Biotech Holding AG director reports initial shareholdings. Christoph Samuel Ziegler filed a Form 3 showing ownership of 7,932 Ordinary Shares of Veraxa Biotech Holding AG. The filing is an initial statement of beneficial ownership and does not report any specific recent purchase or sale transactions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ziegler Christoph Samuel

Role Director

Type	Security	Shares	Price	Value
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Ordinary Shares — 7,932 shares (Direct)

Key Figures

Director shareholding: 7,932 Ordinary Shares Reported buy transactions: 0 shares Reported sell transactions: 0 shares

3 metrics

Director shareholding 7,932 Ordinary Shares Total shares beneficially owned following reported holdings

Reported buy transactions 0 shares Form 3 transaction summary buyShares

Reported sell transactions 0 shares Form 3 transaction summary sellShares

Key Terms

Form 3, Ordinary Shares, beneficial ownership, direct or indirect ownership code

4 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): {"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Ordinary Shares financial

""security_title": "Ordinary Shares","

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

beneficial ownership regulatory

""holdingEntries": 1, "netBuySellDirection": "neutral" (initial beneficial ownership)"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

direct or indirect ownership code regulatory

""direct_or_indirect": "D", "ownership_code": "D""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Veraxa Biotech (VRXA) disclose in this Form 3 filing?

The Form 3 shows director Christoph Samuel Ziegler’s initial beneficial ownership of Veraxa Biotech. He reports holding 7,932 Ordinary Shares, giving investors a baseline view of his direct equity stake at the time of becoming a reporting insider.

How many Veraxa Biotech (VRXA) shares does Christoph Samuel Ziegler own?

Christoph Samuel Ziegler reports owning 7,932 Ordinary Shares of Veraxa Biotech Holding AG. This figure reflects his direct beneficial holdings as disclosed in the Form 3, providing a snapshot of his equity position when he became subject to reporting rules.

Does the Veraxa Biotech (VRXA) Form 3 show recent insider buying or selling?

The Form 3 functions as an initial ownership statement and does not list any specific buy or sell transactions. It simply records Christoph Samuel Ziegler’s existing holding of 7,932 Ordinary Shares when he became an insider required to report.

What type of security does the Veraxa Biotech (VRXA) insider hold?

The insider, Christoph Samuel Ziegler, holds Ordinary Shares of Veraxa Biotech Holding AG. The Form 3 discloses a direct beneficial ownership position of 7,932 Ordinary Shares, clarifying that his stake is in the company’s common equity rather than derivatives.

Is the ownership in Veraxa Biotech (VRXA) held directly or indirectly?

The Form 3 labels Christoph Samuel Ziegler’s 7,932-share position as direct ownership, using the ownership code “D.” Direct ownership means the shares are held in his own name rather than through a trust, partnership, or other intermediary entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 09:28 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ziegler Christoph Samuel

(Last) (First) (Middle)

TALACKER 35

(Street)

ZURICH 8001

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2026

3. Issuer Name and Ticker or Trading Symbol
Veraxa Biotech Holding AG [ VRXA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	7,932	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/Christoph Ziegler	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)